Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + haemophilus influenzae type b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria toxoid + tetanus toxoid + haemophilus influenzae type b conjugate vaccine is a combination vaccine used for the active immunization of infants and children against diphtheria, tetanus, and invasive diseases caused by *Haemophilus influenzae* type b (Hib). This formulation is specifically indicated for pediatric patients in whom the pertussis component (found in standard DTaP-Hib vaccines) is contraindicated or not desired. The vaccine works by inducing the production of specific IgG antibodies: the diphtheria and tetanus toxoids (formalin-inactivated toxins) provide protection against the systemic effects of *Corynebacterium diphtheriae* and *Clostridium tetani*, while the Hib component—comprising the polyribosylribitol phosphate (PRP) capsular polysaccharide conjugated to a carrier protein—elicits a T-cell dependent immune response against Hib, which is a major cause of meningitis and pneumonia in young children.
- Brand names
- DT-Hib
- Other names
- Diphtheria-Tetanus-Hib vaccineDT-Hib vaccine
02
Targets
TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + haemophilus influenzae type b conjugate vaccine.